Skip to content


  • Poster presentation
  • Open Access

The role of antibodies to mutated citrulinated vimentin (anti-MCV) in juvenile idiopathic arthritis patients

  • 1,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P69

  • Published:


  • Public Health
  • Arthritis
  • Outcome Variable
  • Elevated Level
  • Disease Duration


Anti-MCV antibodies (Ab) have high sensitivity and prognostic value in patients with RA. We attempt to correlate positive anti-MCV Ab in different subtypes of JIA patients with six core outcome variables.

Patients and methods

Anti-MCV Ab and Anti-CCP Ab were tested by ELISA (Orgentec, Germany) in sera from 57 JIA, and 14 control patients (12 patients with SLE, 1 with MCTD and 1 with synovial cyst). (16 boys, 41 girls), The mean age was 11,2 years (range 2,5–18,0), and mean disease duration was 3, 4 years (SD ± 2.9). Cut off value ≥ 20 U/mL was considered positive.


Positive anti-MCV Ab were detected in only 3/58 (5,2%) JIA patients, and were significantly elevated in two RF positive polyartritis patients, and slightly elevated in 1/19 (5,3%) patients with enthesitis-related arthritis (ErA). Among all patients, anti-CCP Ab were positive only in one anti-MCV positive polyarticular JIA patient. Anti-MCV and RF positivity correlated statistically (r = 0,504, P = 0,028) in ErA, while no association between anti-MCV Ab and six core outcome variables was observed in this, or other JIA subtypes. Unexpectedly, anti-MCV was detected in 3/12 (25%) SLE patients (2 low positive and 1 significantly positive), and in 1 patient with MCTD. All of these patients were both RF and anti-CCP negative.


In contrast to RA, anti-MCV antibodies are not specific for JIA. However, within JIA patients, significantly elevated levels are almost exclusively found in two RF positive, polyarticular patients.

Authors’ Affiliations

Children's Hospital Zagreb, Zagreb, Croatia
Clinical Institute of Chemistry School of Medicine University of Zagreb, Sestre milosrdnice University Hospital, Zagreb, Croatia


  1. Innala L, Kokkonen H, Eriksson C, Jidell E, Berglin E, Dahlqvst SR: Antibodies Against Mutated Citrullinated Vimentin Are a Better Predictor of Disease Activity at 24 Months in Early Rheumatoid Arthritis Than Antibodies Against Cyclic Citrullinated Peptides. J Rheumatol. 2008 Apr 1,Google Scholar
  2. Mathsson L, Mullazehi M, Wick MC, Sjöberg O: Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis Rheum. 2008, 58 (1): 36-45. 10.1002/art.23188.View ArticlePubMedGoogle Scholar


© Lamot et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.